ArticleMayo Clinic proceedings2020
Coronary Artery Bypass Grafting in Cancer Patients: Prevalence and Outcomes in the United States.
Article in Mayo Clinic proceedings, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 24 citations in OpenAlex.
- The intersection of colorectal cancer and cardiovascular disease: shared mechanisms and clinical implications.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Review
- Revascularisation in Patients with Cancer: A Review.European cardiology · 2026Review
- Hybrid Revascularization Approach in a Patient With Cancer Metastatic to the Sternum.JACC. Case reports · 2025Article
- Short-Term Outcomes of Patients with Non-Metastatic Malignant Solid Tumor after Coronary Artery Bypass Grafting: A Population-Based Study of National/Nationwide Inpatient Sample From 2015 To 2020.Brazilian journal of cardiovascular surgery · 2025Article
- Balancing anticancer therapy efficacy and safety in advanced hepatocellular carcinoma: a case report.Journal of gastrointestinal oncology · 2024Article
- Transcatheter Aortic Valve Replacement in Patients With or Without Active Cancer.Journal of the American Heart Association · 2023Article
- Dual Antiplatelet Therapy and Cancer; Balancing between Ischemic and Bleeding Risk: A Narrative Review.Journal of cardiovascular development and disease · 2023Review
- Screening for Coronary Artery Disease in Cancer Survivors:JACC. CardioOncology · 2023Review
- Coronary artery disease, left ventricular function and cardiac biomarkers determine all-cause mortality in cancer patients-a large monocenter cohort study.Clinical research in cardiology : official journal of the German Cardiac Society · 2023Article
- Challenges and Management of Acute Coronary Syndrome in Cancer Patients.Frontiers in cardiovascular medicine · 2021Review
Corrections and comments
- Commented on by
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
Abstract
objectiveTo characterize the contemporary efficacy and utilization patterns of coronary artery bypass grafting (CABG) in specific cancer types.
methodsWe leveraged the data from the National Inpatient Sample and plotted trends of utilization and outcomes of isolated CABG (with no other additional surgeries during the same hospitalization) procedures from January 1, 2003, through September 1, 2015. Propensity score matching was used to assess for potential differences in outcomes by type of cancer status among contemporary (2012-2015) patients.
resultsOverall, the utilization of CABG decreased over time (250,677 in 2003 vs 134,534 in 2015, P<.001). However, the proportion of those with comorbid cancer increased (7.0% vs 12.6%, P<.001). Over time, in-hospital mortality associated with CABG use in cancer remained unchanged (.9% vs 1.0%, P=.72); yet, cancer patients saw an increase in associated major bleeding (4.5% vs 15.3%, P<.001) and rate of stroke (.9% vs 1.5%, P<.001) over time. In-hospital cost-of-care associated with CABG-use in cancer also increased over time ($29,963 vs $33,636, P<.001). When stratified by cancer types, in-hospital mortality was not higher in breast, lung, prostate, colon cancer, or lymphoma versus non-cancer CABG patients (all P>.05). However, there was a significantly higher prevalence of major bleeding but not stroke in patients with breast and prostate cancer only compared with non-cancer CABG patients (P<.01). Discharge dispositions were not found to be different between cancer sub-groups and non-cancer patients (P>.05), except for breast cancer patients who had lower home care, but higher skilled care disposition (P<.001).
conclusionAmong those undergoing CABG, the prevalence of comorbid cancer has steadily increased. Outside of major bleeding, these patients appear to share similar outcomes to those without cancer indicating that CABG utilization should be not be declined in cancer patients when otherwise indicated. Further research into the factors underlying the decision to pursue CABG in specific cancer sub-groups is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.